- Home
- ALXO vs REFI Comparison
ALXO vs REFI Comparison
Compare ALXO & REFI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALXO | REFI |
|---|---|---|
| Founded | 2015 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 205.9M | 241.1M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ALXO | REFI |
|---|---|---|
| Price | $1.94 | $9.76 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $3.50 | N/A |
| AVG Volume (30 Days) | ★ 818.2K | 138.4K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 15.79% |
| EPS Growth | ★ 26.36 | N/A |
| EPS | N/A | ★ 0.23 |
| Revenue | N/A | ★ $48,857,628.00 |
| Revenue This Year | N/A | $17.47 |
| Revenue Next Year | N/A | $0.06 |
| P/E Ratio | ★ N/A | $42.70 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.51 | $9.77 |
| 52 Week High | $2.66 | $14.57 |
Technical Indicators
Market Signals| Indicator | ALXO | REFI |
|---|---|---|
| Relative Strength Index (RSI) | 46.61 | 27.12 |
| Support Level | $1.56 | N/A |
| Resistance Level | $2.27 | $12.45 |
| Average True Range (ATR) | 0.13 | 0.21 |
| MACD | -0.03 | -0.05 |
| Stochastic Oscillator | 22.58 | 5.59 |
Price Performance
Historical ComparisonAbout ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
About REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. The Company operates as one operating segment, and its primary investment objective is to provide attractive, risk-adjusted returns for stockholders over time, mainly through consistent current income (dividends and distributions) and secondarily, through capital appreciation. The company operates mainly within the USA itself.